🇺🇸 FDA
Patent

US 6258845

DFMO and sulindac combination in cancer chemoprevention

expired A61KA61K31/19A61K31/195

Quick answer

US patent 6258845 (DFMO and sulindac combination in cancer chemoprevention) held by Arizona Board of Regents on Behalf of the University of Arizona expires Mon Jul 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Arizona Board of Regents on Behalf of the University of Arizona
Grant date
Tue Jul 10 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/19, A61K31/195, A61P, A61P35/00